Illumina, Inc. vs OneSpan Inc — how do they compare? Illumina, Inc. trades at $191.08 (market cap $29.12B), while OneSpan Inc trades at $16.23 (market cap $600.69M). The key difference: Illumina, Inc. is far larger — about 48.5× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | OSPN | |
|---|---|---|
Market Cap | $29.12B | $600.69M |
Sector | Health | Technology |
52-Week High | $205.10 | $16.78 |
52-Week Low | $91.00 | $10.15 |
Enterprise Value | $30.48B | $569.77M |
Dividend Yield | — | 3.19% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
OneSpan (OSPN) trades at $16.21, down 0.98% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 9.21, net income margin of 27.76%, and consistent earnings beats in recent quarters. Recent Q2 2026 results showed revenue growth and raised full-year guidance, while the company continues paying $0.13 quarterly dividends.
Outlook remains positive with 67% analyst buy ratings and $17 consensus target offering 5% upside. Key risks include declining net cash flow and competitive pressures in the software sector. The stock presents value opportunity given attractive valuation multiples and strong profitability metrics, though investors should monitor execution against raised guidance.
Trailing returns across standard periods
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →